Poseltinib
Highest phase reached
Phase 2
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Small molecule
- Drug name
- Poseltinib
- Molecular weight
- 470.53
- Structure (SMILES)
- C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C)CC4)cc3)nc3ccoc23)c1
- glofitamab poseltinib lenalidomide
- hm 71224
- Hm-71224
- hm71224
- HM71224
- ly3337641
- Ly3337641
- LY3337641
- LY3337641 (T1)
- LY3337641 (T2)
- NB02 (Poseltinib)
- poseltinib
- Poseltinib
- poseltinib [INN]
- Poseltinib [WHO-DD]
- poseltinib inn
- poseltinib who dd
- CAS registry numbers
- 1353552-97-2
- ChEMBL ID
- CHEMBL4163691
- InChIKey
- LZMJNVRJMFMYQS-UHFFFAOYSA-N
- PubChem compound IDs
- 56644522
- FDA ingredient codes (UNII)
- D01E4B1U35
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- poseltinib
- Type
- Synthetic organic
- Drug name stem
- -tinib
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- Janus kinase 3
- Gene symbol
- JAK3
- Protein identifier
- P52333
- Median affinity
- 7.3
- Affinity units
- pIC50
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- Bruton tyrosine kinase
- Gene symbol
- BTK
- Protein identifier
- Q06187
- Median affinity
- 7.3
- Affinity units
- pIC50
- Mechanism
- Tyrosine-protein kinase BTK inhibitor
- Action type
- Inhibitor
- Target
- Tyrosine-protein kinase BTK
- Protein identifier
- Q06187
Open Targets mechanisms
- Mechanism
- Tyrosine-protein kinase BTK inhibitor
- Action type
- Inhibitor
- Target
- Tyrosine-protein kinase BTK
Investigated indications
- Condition
- Arthritis, Rheumatoid
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000685
- Subject identifier
- D001172
- Condition identifier
- EFO_0000685
- Highest recorded phase
- 2
- Condition identifier
- EFO_0005952
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0002571
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0008383
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0017604
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0018876
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0018905
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0018906
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0018908
- Highest recorded phase
- 1
- NCT01765478
- NCT02628028
- Hydrogen bond acceptors
- 8
- Hydrogen bond donors
- 2
- Polar surface area
- 95.76
- Calculated partition coefficient (ALogP)
- 4.64
- Calculated partition coefficient (XLogP)
- 4.1
- Prodrug
- No
- Chirality
- Achiral
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 7
- Heavy atoms
- 35
- Molecular formula
- C26H26N6O3
- Monoisotopic mass
- 470.20663871
- Natural product
- No
- Recorded assays
- 8
- Active assays
- 7
- Confirmatory
- Other
Related records
Trials (20)
- 19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers
- A Study in Healthy Male Volunteers to Investigate the Safety and Tolerability of a Single Dose of Neosaxitoxin Alone and in Combination With Bupivacaine (With and Without Epinephrine) for Brachial Plexus Blockade
- A Study in Healthy Men That Tests if Taking BI 1265162 by Mouth, Intravenously, or Inhaled Influences the Amount of BI 1265162 in the Blood
- A Study in Healthy People to Compare 2 Different Formulations of BI 1015550 Taken With or Without Food
- A Study in Healthy People to Test if Taking Different Formulations of BI 425809 Tablets Influences the Amount of BI 425809 in the Blood
- A Study of LY3337641 in Healthy Male Participants
- A Study of LY3337641 in Healthy Participants
- A Study of LY3337641 in Japanese and Caucasian Healthy Participants
- A Study of LY3337641 in Rheumatoid Arthritis
- A Study on Whether Patients Prefer the Spiriva® Respimat® or the Spiriva® Handihaler® for Treating Their Chronic Obstructive Pulmonary Disease (COPD)
- A Study to Evaluate the Pharmacokinetics Similarity of CBP-201 in Healthy Adult Chinese Subjects
- Bioavailability and Safety of Two Oral Fixed Dose Preparations Containing 18 mg Ivermectin (IVM 18 MG TABLETS, LICONSA S.A., Spain) Versus Reference Dosing (Weight Based) Containing 6 mg Ivermectin (REVECTINA®, Abbott Laboratórios do Brasil Ltda, Brazil)
- Bioequivalence Study to Compare Selexipag 400 Microgram Film Coated Tablets Versus Uptravi® (Selexipag) 400 Microgram Film Coated Tablets
- Efficacy Study of T2 Versus AZA to Maintain Clinical and Endoscopic Remission in Postoperative Crohn's Disease
- Golcadomide, Poseltinib, and Rituximab for Relapsed/Refractory Diffuse Large B-cell Lymphoma
- GPL in Patients with Relapsed/refractory Diffuse Large B Cell Lymphoma
- NB02(POSELTINIB) Monotherapy in R/R Non-Hodgkin's Lymphoma
- Safety, Tolerability, Pharmacokinetics of Single Rising Oral Doses of BI 1181181 in Healthy Male Volunteers, Including Investigation of the Effect of Food on the Bioavailability of BI 1181181
- Safety,PK/PD, Food Effect Study of Orally Administered HM71224 in Healthy Adult Male Volunteers
- Study of 19(T2)28z1xx TRAC-Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Lymphoma
In development for (2)
- Non-Hodgkin lymphoma Phase 1
- Rheumatoid arthritis Phase 2
Targets (1)
- BTK Tyrosine-protein kinase BTK inhibitor